Representative Data = More Complete Outcomes 

Data gaps don’t start at analysis- they start with who has the opportunity to participate. 

When certain populations are not included in clinical trials, they don’t just impact enrollment- they are missing from the data entirely. Traditional site models often limit participation, resulting in datasets that don’t fully reflect the populations therapies are intended to serve. 

Community-based clinical trials expand participation from the start of the study. 

By operating within local communities, CBCTs enable broader inclusion across age, ethnicity, and socioeconomic background. This leads to broader participation and datasets that more accurately reflect real-world patient populations. 

This impact is reflected in the data. Broader participation leads to more complete datasets and outcomes that better reflect real-world populations, particularly as regulatory expectations continue to evolve. 

This is where the full value of the model becomes clear. Data quality is shaped by who is included in the trial- and who is not. 

👉 Explore how enrollment, retention, and data are connected: The Triple Effect of Community-Based Clinical Trials - EmVenio